Companies Praxis Precision Medicines, Inc.
Praxis Precision Medicines (PRAX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Praxis Precision Medicines, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,120,512FY2023
- $13,427,668FY2024
- $8,708,648FY2025
CEO total pay was $8,708,648 in fiscal 2025, down from $13,427,668 in fiscal 2024.
FY2025: salary $659,200 · bonus $0 · stock awards $2,368,125 · option awards $3,691,125
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Marcio Souza | $659,200 | $0 | $2,368,125 | $3,691,125 | $1,483,200 | $0 | $506,998 | $8,708,648 |
| President and Chief Executive Officer | ||||||||
| Timothy Kelly | 526,845 | 0 | 789,375 | 1,230,375 | 632,215 | 0 | 22,384 | 3,201,194 |
| Chief Financial Officer | ||||||||
| Alex Nemiroff | 456,228 | 0 | 710,438 | 1,107,338 | 547,474 | 0 | 22,305 | 2,843,783 |
| General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Marcio Souza | $8,708,648 | $13,427,668 | $2,120,512 | ↓ −4,719,020 |
| Timothy Kelly | 3,201,194 | 4,044,861 | 1,023,800 | ↓ −843,667 |
| Alex Nemiroff | 2,843,783 | 3,918,084 | 843,105 | ↓ −1,074,301 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The executive compensation program is built on a strong pay-for-performance philosophy designed to align the financial interests of executive officers with those of stockholders by linking a significant portion of compensation to long-term, performance-based outcomes. The program aims to attract, motivate, and retain key personnel by providing a competitive total compensation package that emphasizes at-risk compensation tied to rigorous corporate goals and long-term value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co., Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Alex Nemiroff | RSU | 2025-01-10 | — | — | 11,250 | — | $710,438 |
| Marcio Souza | RSU | 2025-01-10 | — | — | 37,500 | — | 2,368,125 |
| Timothy Kelly | RSU | 2025-01-10 | — | — | 12,500 | — | 789,375 |
| Alex Nemiroff | OPTION | 2025-01-10 | — | — | 22,500 | — | 1,107,338 |
| Marcio Souza | OPTION | 2025-01-10 | — | — | 75,000 | — | 3,691,125 |
| Timothy Kelly | OPTION | 2025-01-10 | — | — | 25,000 | — | 1,230,375 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Alex Nemiroff | $710,438 | $0 | $1,107,338 | 0.0% |
| Marcio Souza | 2,368,125 | 0 | 3,691,125 | 0.0% |
| Timothy Kelly | 789,375 | 0 | 1,230,375 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Timothy Kelly | Option | 116 | 271.65 | — |
| Alex Nemiroff | RSU | 300 | — | 88,422 |
| Marcio Souza | Option | 358 | 271.65 | — |
| Timothy Kelly | RSU | 400 | — | 117,896 |
| Alex Nemiroff | Option | 539 | 31.8 | — |
| Timothy Kelly | Option | 540 | 31.8 | — |
| Marcio Souza | Option | 854 | 31.8 | — |
| Marcio Souza | RSU | 1,233 | — | 363,414 |
| Alex Nemiroff | Option | 2,181 | 44.4 | — |
| Timothy Kelly | Option | 2,715 | 44.4 | — |
| Timothy Kelly | RSU | 5,850 | — | 1,724,229 |
| Alex Nemiroff | RSU | 5,850 | — | 1,724,229 |
| Marcio Souza | Option | 7,680 | 44.4 | — |
| Timothy Kelly | Option | 7,813 | 43.37 | — |
| Alex Nemiroff | Option | 7,813 | 43.37 | — |
| Alex Nemiroff | RSU | 11,250 | — | 3,315,825 |
| Timothy Kelly | RSU | 12,500 | — | 3,684,250 |
| Timothy Kelly | Option | 18,201 | 56.94 | — |
| Alex Nemiroff | Option | 18,201 | 56.94 | — |
| Alex Nemiroff | Option | 22,500 | 63.15 | — |
| Timothy Kelly | Option | 25,000 | 63.15 | — |
| Marcio Souza | Option | 26,042 | 43.37 | — |
| Marcio Souza | RSU | 37,500 | — | 11,052,750 |
| Marcio Souza | Option | 75,000 | 63.15 | — |
| Marcio Souza | Option | 92,501 | 56.94 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dean MitchellIndependent · Board Chair · Compensation · Science and Technology | $86,500 | — | $358,721 | — | — | $445,221 |
| Gregory NordenIndependent · Audit (Chair) · Compensation | 67,500 | — | 358,721 | — | — | 426,221 |
| Jill DeSimoneIndependent · Audit · Nominating and Corporate Governance | 62,500 | — | 358,721 | — | — | 421,221 |
| William YoungIndependent · Compensation (Chair) · Nominating and Corporate Governance | 60,000 | — | 358,721 | — | — | 418,721 |
| Jeffrey Chodakewitz, M.DIndependent · Nominating and Corporate Governance (Chair) · Science and Technology | 54,000 | — | 358,721 | — | — | 412,721 |
| Marcio SouzaEmployee director | — | — | — | — | — | 0 |
| Stuart ArbuckleIndependent · Compensation · Science and Technology · Newly elected | — | — | — | — | — | — |
| Jeffrey KindlerIndependent · Audit · Nominating and Corporate Governance · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $330,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $330,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Praxis Precision Medicines as a peer
Companies that benchmark against PRAX
4 companies name PRAX as a compensation peer
- Definium Therapeutics, Inc.DFTXFY2025
- LEXICON PHARMACEUTICALS, INC.LXRXFY2025
- NEKTAR THERAPEUTICSNKTRFY2025
- Olema Pharmaceuticals, Inc.OLMAFY2025
Each company listed discloses PRAX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PRAX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Avidity Biosciences, Inc. | 2024 | Sarah Boyce | $659,900 | $10,748,480 | $2,157,090 | $594,000 | $14,176,480 |
| 2 | Praxis Precision Medicines, Inc. | 2025 | Marcio Souza | 659,200 | 2,368,125 | 3,691,125 | 1,483,200 | 8,708,648 |
| 3 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 4 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 5 | Beam Therapeutics Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 6 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 7 | Dyne Therapeutics, Inc. | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 8 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Praxis Precision Medicines, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Avidity Biosciences, Inc. | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine |
| Beam Therapeutics Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dyne Therapeutics, Inc. | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 24,054,017 | 824,318 | 29,929 | 96.69% | Passed |
| 2025 | 2025-06-26 | 10,671,320 | 6,919,705 | 3,349 | 60.66% | Passed |
| 2024 | 2024-06-05 | 10,040,059 | 4,137,994 | 4,130 | 70.81% | Passed |
| 2022 | 2022-05-26 | 35,107,181 | 1,706,990 | 19,469 | 95.36% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 96.69%a |
| 2025 | 2025-06-26 | 60.66%b |
| 2024 | 2024-06-05 | 70.81%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 23 : 1 |
|---|---|
| CEO total compensation | $8,708,648 |
| Median employee compensation | $371,291 |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (32 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Marcio Souza. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · page 27. As printed: 8,708,648. View filing ↗
- Section 01, Timothy Kelly. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 3,201,194. View filing ↗
- Section 01, Alex Nemiroff. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 2,843,783. View filing ↗
- Section 03, Alex Nemiroff RSU. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Marcio Souza RSU. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Timothy Kelly RSU. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Alex Nemiroff OPTION. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Marcio Souza OPTION. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Timothy Kelly OPTION. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-30. Section “CEO Pay Ratio”. As printed: 23 : 1. View filing ↗
- Section 08, Dean Mitchell. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 445,221. View filing ↗
- Section 08, Gregory Norden. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 426,221. View filing ↗
- Section 08, Jill DeSimone. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 421,221. View filing ↗
- Section 08, William Young. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 418,721. View filing ↗
- Section 08, Jeffrey Chodakewitz, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 412,721. View filing ↗
- Section 08, Marcio Souza. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Stuart Arbuckle. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: —. View filing ↗
- Section 08, Jeffrey Kindler. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 96.69% (votes for as printed: 24,054,017). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-27. Item 5.07 · say-on-pay result. As reported: 60.66% (votes for as printed: 10,671,320). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-06. Item 5.07 · say-on-pay result. As reported: 70.81% (votes for as printed: 10,040,059). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 330,500 + equity 0 + all other 0 = 330,500, summed across the director compensation table rows.
- Avidity Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Avidity Biosciences, Inc.'s own proxy. As printed: 14,176,480. View filing ↗
- Praxis Precision Medicines, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Praxis Precision Medicines, Inc.'s own proxy. As printed: 8,708,648. View filing ↗
- Arvinas, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- Beam Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Beam Therapeutics Inc.'s own proxy. As printed: 5,818,525. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Dyne Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗